Psychedelic-Assisted Psychotherapy

Psychedelic-Assisted Psychotherapy is a radical innovation disrupting the psychiatric landscape with better, safer and faster treatments. Neuroscience shows that the responsible use of psilocybin and MDMA in a few supervised sessions trigger powerful experiences with lasting positive outcomes. Scaling these treatments require education and training of mental health professionals worldwide.

Psychedelic-Assisted Psychotherapy is a paradigmatic shift in the psychiatric landscape. A few treatment sessions administering psychoactive substances which induces temporary changes in mood, perception, cognition and consciousness has resulted in better and faster results than medication or psychotherapy alone. Phaneros helps to solve the upcoming challenge to move research from small-scale Phase 2 studies to large-scale Phase 3 while at the same time training mental health professionals to adequately, safely and responsibly use these new treatment approaches. Combining professional training with clinical R&D, we will push these treatments toward official approval and increasing availability worldwide, in the shortest time possible.

The recent trend of increasing studies with psychedelic treatmens is very encouraging. However, most research has been and is currently funded by private donations to non-profit organisations, which can unfortunately limit the scale and reach of these developments. After a decade working in this field I am developing a new model to make this research financially sustainable. My solution is simple yet powerful: to invest revenue from state-of-the-art medical training for mental health professionals in the required R&D, thus generating more revenue to all stakeholders from treatments provided after government approval.

The beneficiaries of my solution are mental health professionals and patients in search of better treatments. Training will be provided to professionals through state-of-the-art courses with near simultaneous execution of the required R&D for drug approval, thus making treatments available for patients in the shortest time possible.

Track subscriptions to our training programs. - Train mental health professionals to use these new treatment approaches.

Obtain government approvals for each stage (Phase 2, Phase 3, etc) - Design and execute clinical trials with trained professionals.

Track number of interested patients. - Provide treatments to patients.

Phaneros is the world's first startup company combining mental health professional training with R&D with psychedelic-assisted psychotherapy, a new powerful and disruptive innovation in psychiatric treatments.

Our approach is focused on having the mental health professionals as our biggest stakeholders. They will be our clients in the training phase and our partners in the R&D and as treatment providers. The whole model will be developed in close partnership with these psychiatrists and therapists, with an approach focused to best serve their needs to provide better treatments. Furthermore, the whole process is geared toward better serving the pressing needs of the final beneficiaries, which are the many mental health patients.

Our solution will be deployed to mental health professionals by state=of=the=art training courses on how to effectively and safely use these new treatment protocols combining psychotherapy with acute psychopharmacology. As we train more professionals, costs for training and therapy will drop, and availability will increase.

We are currently applying for seed investment so we can join an international clinical trial. This will largely reduce costs for us to have our first protocol to train professionals and to treat patients approved in Brazil. From there on we will reinvest part of the revenue into research with new protocols and training of more professionals, increasing our revenue while at the same time reducing costs for professional training and patient treatment due to volume increase.

Current paucity of investment in the initial and riskier phase toward having the first treatment approved.

I am currently looking for partners to help mature the business model, fund the first and most riskier steps and execute the first few cycles.

The Multidisciplinary Association for Psychedelic Studies (MAPS)